BYDUREON Drug Patent Profile

When do Bydureon patents expire, and what generic alternatives are available?

Bydureon is a drug marketed by Astrazeneca Ab and is included in two NDAs. There are seven patents protecting this drug.

This drug has three hundred and seven patent family members in forty-eight countries.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the exenatide synthetic profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bydureon

A generic version of BYDUREON was approved as exenatide synthetic by AMNEAL on November 19^th, 2024.

Summary for BYDUREON

International Patents:	307
US Patents:	6
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	35
Clinical Trials:	40
Patent Applications:	236
Drug Prices:	Drug price information for BYDUREON
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BYDUREON
What excipients (inactive ingredients) are in BYDUREON?	BYDUREON excipients list
DailyMed Link:	BYDUREON at DailyMed

See drug prices for BYDUREON

See drug sales revenues for BYDUREON

Recent Clinical Trials for BYDUREON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Christopher D. Verrico	PHASE1
The University of Texas Health Science Center, Houston	Phase 2
University of Washington	Phase 3

See all BYDUREON clinical trials

US Patents and Regulatory Information for BYDUREON

BYDUREON is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		DISCN	Yes	No					Y
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		DISCN	Yes	No					Y
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		DISCN	Yes	No					Y
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		DISCN	Yes	No					Y
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		DISCN	Yes	No					Y
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		DISCN	Yes	No					Y
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		DISCN	Yes	No					Y

Expired US Patents for BYDUREON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012

International Patents for BYDUREON

When does loss-of-exclusivity occur for BYDUREON?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Chile

Denmark

European Patent Office

Japan

Mexico

Serbia

Slovenia

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BYDUREON around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	026024	COMPUESTOS INHIBIDORES SGLT2 DE GLUCOSIDOS DE C-ARILO Y METODO, LAS COMPOSICIONES FARAMCEUTICAS QUE LOS CONTIENEN Y LOS INTERMEDIARIOS DE SINTESIS DEDICHOS COMPUESTOS
Argentina	040032	C-ARIL-GLUCOSIDOS COMO INHIBIDORES DE SGLT2 Y METODO
Austria	295848
Austria	353334
Australia	2003237886	C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD
Australia	781009
Australia	7848300	C-aryl glucoside sglt2 inhibitors

Supplementary Protection Certificates for BYDUREON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1506211	C300585	Netherlands		PRODUCT NAME: DAPAGLIFLOZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/12/795/001-010 20121112
1506211	PA2013008	Lithuania		PRODUCT NAME: DAPAGLIFLOZINUM; REGISTRATION NO/DATE: EU/1/12/795/001 - EU/1/12/795/010 20121112
1506211	122013000033	Germany		PRODUCT NAME: DAPAGLIFLOZIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/12/795/001-010 20121112
1506211	C20130006 00074	Estonia		PRODUCT NAME: DAPAGLIFLOZIN;REG NO/DATE: K(2012)8378 12.11.2012
1506211	92182	Luxembourg		PRODUCT NAME: DAPAGLIFLOZINE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
1506211	2013/013	Ireland		PRODUCT NAME: DAPAGLIFLOZIN AND PHARACEUTICALLY ACCEPTABLE SALTS THREOF; REGISTRATION NO/DATE: EU/1/12/795/001-010 20121112
1506211	CA 2013 00019	Denmark

Last updated: July 20, 2026

BYDUREON market dynamics and financial trajectory: sales trends, payer pressure, and exclusivity-driven erosion

BYDUREON (exenatide extended-release; Amylin/BMS; marketed by AstraZeneca in the US and other regions historically via licensing) has faced a sustained share shift from injectable GLP-1 receptor agonists with better dosing convenience and broader formularies. The product’s revenue path has been dominated by (1) competitive displacement from once-weekly and once-daily GLP-1s and (2) later-cycle pressure from payer preferred-drug lists and step-edit rules, with a further risk profile tied to long-term exclusivity and competitive entry of other exenatide ER products and GLP-1 alternatives. Overall, BYDUREON’s commercial trajectory is best characterized as mature-product decline rather than growth, with periodic re-framing around formulary position, device experience, and co-pay support where available.

---

What is the BYDUREON revenue history and why did sales decline?

How BYDUREON sold in practice: label breadth vs competitive convenience

BYDUREON’s core value proposition was glucose control and weight benefit in type 2 diabetes as an injectable GLP-1 class therapy with once-weekly administration. In the market, that value narrowed as competitors raised the bar on:

• Injection frequency consistency and pen usability
• Hemoglobin A1c reduction depth
• Cardiovascular and kidney outcome evidence across major GLP-1 players
• Lower real-world patient friction driven by smaller devices, improved injection experience, and automated dosing workflows
• Payer-managed access via preferred tiers and restrictive prior authorization

Key drivers of erosion

1. Formulary steering to newer GLP-1s
   Payer formularies progressively favored agents with stronger outcomes evidence and preferred positioning. BYDUREON’s exenatide ER profile became harder to justify as payers shifted coverage toward agents with broader guideline alignment and market “standard-of-care” momentum.

2. Device and adherence friction
   BYDUREON’s reconstitution-era delivery approach historically underperformed patient and prescriber expectations versus pen-based alternatives. Device usability became a differentiator in switching decisions, especially when payers required trial of preferred agents.

3. Class competition intensified
   The GLP-1 market moved from early adoption into crowded lanes: multiple once-weekly GLP-1s, then dual and triple incretin combinations later. In that environment, BYDUREON’s incremental differentiation eroded.

4. Discounting and co-pay dynamics
   Mature injectable diabetes brands often rely on net price management and payer contracting to preserve access. Over time, increased competitive intensity tends to compress net sales even when gross prescriptions remain stable.

---

Which competitors most impacted BYDUREON market share and net price?

Class-wide displacement: newer GLP-1s and incretin combinations

BYDUREON’s displacement risk increased as these categories gained preferred access in commercial formularies and Medicare Part D:

• Once-weekly GLP-1 receptor agonists (dose convenience and preferred tier positioning)
• Oral GLP-1 and other diabetes agents where payers broadened options
• Later-cycle incretin combinations and product line expansions that offered stronger value propositions for outcomes and weight management

Switching dynamics: what moved patients

Real-world switching typically followed a predictable pattern:

• Patients started on preferred products after initial diagnosis
• Existing BYDUREON users were nudged by prior authorization and formulary changes
• Pharmacy benefit managers pushed step edits requiring trial of preferred GLP-1s before coverage of BYDUREON

Net pricing pressure

When BI and PBMs require formulary compliance, net pricing becomes less controllable. BYDUREON’s financial trajectory reflects the typical mature-diabetes injectable pattern: higher rebates and contracting costs to retain access, then net price compression as preferred options dominate.

---

What payer and reimbursement dynamics shaped BYDUREON’s commercial trajectory?

Commercial and Medicare access

• Commercial formularies: BYDUREON faced tier movement and step therapy as other GLP-1s took preferred slots.
• Medicare Part D: Plan formularies and utilization management moved patients toward better-covered GLP-1s, with BYDUREON coverage increasingly contingent on prior authorization or documented failure of preferred alternatives.

Prior authorization and step edits

Payer policies commonly applied:

• Step therapy (trial/failure of preferred GLP-1)
• Prior authorization tied to diagnosis documentation and sometimes A1c or weight-related criteria
• Quantity or days-supply edits based on dose scheduling norms

Impact on prescribing

The prescribing impact was not just clinical. It was procedural:

• Longer approvals reduced “new start” velocity
• Switching required administrative steps and clinical justifications
• Formularies created a predictable switching cycle after each annual bid cycle and formulary refresh

---

When did BYDUREON lose exclusivity, and how does exclusivity erosion affect pricing?

How exclusivity loss typically transmits into sales decline

Exclusivity erosion in injectable diabetes brands tends to accelerate:

• Loss of formulary priority
• Higher price competition through authorized generics or follow-on branded products with aggressive contracting
• Reduction in co-pay support effectiveness because patients and prescribers migrate toward covered options

What matters for BYDUREON-specific economics

For mature injectables, the biggest financial impact is rarely the first legal threat alone. It is the months-to-year period after when payers redesign formularies around competitive availability and when PBM contracting shifts net prices.

---

What does the BYDUREON US market look like under FDA and Orange Book status?

Orange Book listings drive timing for generic and follow-on competition

The Orange Book status shapes the “event horizon” for potential ANDA entry under Hatch-Waxman. For BYDUREON, the market dynamic is consistent with mature GLP-1 injectables where:

• Patent estates and exclusivity determine whether generic entry is allowed immediately
• Court outcomes and settlement terms control effective launch timing
• Even where generic entry is blocked for a period, payer behavior begins “front-running” competitive risk by moving to alternative covered options earlier

Net market effect

If competitive entry is anticipated, PBMs often shift preferencing before the first AB-rated product appears. That shortens the remaining commercial runway even before legal barriers fall.

---

How does BYDUREON compare with competing exenatide formulations and GLP-1 delivery systems?

Comparison by dosing and device

In the GLP-1 injectable market, device and patient workflow matter as much as molecule:

• Pen systems increase usability and reduce injection preparation time.
• Reduced patient friction improves persistence and improves payer willingness to keep coverage.

Exenatide ER positioning risk

Even within the exenatide category, follow-on formulations and competitor pens can shift patients away from BYDUREON if they offer:

• Better handling
• Similar efficacy with improved user experience
• Better contracting terms that lower PBM net cost

Commercial result

BYDUREON’s competitive position weakened as the market shifted toward more streamlined injection platforms and broad outcomes evidence.

---

What product life-cycle metrics matter for BYDUREON investors and licensors?

The financial indicators to track

1. TRx and script share trends: class share growth in preferred products correlates with BYDUREON decline.
2. Net price and rebate rate movement: net sales compression often shows before unit declines in late lifecycle.
3. Formulary position: preferred vs non-preferred status is a leading indicator.
4. Utilization management tightness: prior authorization and step edits increase as competitors become available.
5. Switching rate: the longer patients remain on treatment, the slower erosion proceeds.

Revenue shape typical for mature GLP-1 injectables

• Peak years followed by gradual TRx decline
• Net sales remaining higher temporarily due to contract structure
• Faster deterioration when payers force switches or when new injectables replace older devices in formulary

---

What patent and litigation events typically affect BYDUREON’s competitive timeline?

How patent estates influence launch calendars

For branded GLP-1 injectables, the typical chain is:

• ANDA or follow-on product filings under relevant exclusivity and patent listings
• Paragraph IV litigation that delays FDA approval and/or commercial entry
• Settlement agreements that define launch dates or “design-around” use

Financial transmission

Even without generic entry, the market reacts to legal timelines:

• PBMs reduce formulary reliance on brands with delayed but likely competition
• Contracting shifts toward alternatives
• Sales force pressure increases, raising SG&A and reducing ROI

---

What are the generic entry risks for BYDUREON, and what does “launch risk” mean financially?

Launch risk definition used in pricing and forecasting

In mature branded injectables, launch risk means:

• PBM re-contracting and formulary redesign
• Patient switching acceleration after competitive availability is credible
• Co-pay program modification and net price reset

Financial consequence

The biggest negative variance usually shows around the period when coverage changes align with competitive entry. That typically yields:

• Sudden prescription loss
• Rapid shift in channel inventory dynamics for injectables
• Higher discounting to preserve remaining coverage

---

What regional dynamics and geographic coverage issues matter for BYDUREON?

US versus international

Commercial performance differs by region due to:

• National reimbursement systems
• Formulary structures
• Competition intensity and device adoption curves
• Local patent status and follow-on product presence

Global competition for GLP-1 therapy

International markets increasingly mirror the US pattern:

• Preferencing shifts toward newer and better-covered agents
• Tender systems and national price negotiations compress branded net revenue
• Older devices lose access as pen-based competitors dominate

---

Key Takeaways

• BYDUREON’s financial trajectory is consistent with a mature GLP-1 injectable: steady erosion driven by payer preferencing, prior authorization/step edits, and competitive convenience and evidence advantages.
• The core market dynamic is not only molecule competition but also formulary positioning and device-driven switching behavior.
• Exclusivity and patent/settlement calendars matter because payers typically adjust coverage ahead of effective entry, accelerating net sales pressure.
• For forecasting and investment decisions, the most decision-relevant signals are TRx share in the broader GLP-1 class, net price/rebate compression, and formulary status changes, which usually lead unit erosion.

---

FAQs

1. Does BYDUREON face higher access barriers than newer once-weekly GLP-1s?

Yes, as payers tightened step therapy and prior authorization toward preferred alternatives with improved formulary position and patient-handling profiles.

2. How do rebates and net price typically change for BYDUREON in late lifecycle?

Net price usually declines as competitive contracting increases, with rebates rising to preserve coverage as preferred brands dominate.

3. Will biosimilar-style dynamics affect BYDUREON?

BYDUREON is not a biologic in the biosimilar sense used for mAbs; competition risk is primarily generic/follow-on and class competition.

4. What is the fastest leading indicator that BYDUREON’s sales will worsen?

A shift of national and plan formularies from preferred to non-preferred with added step edits usually precedes measurable prescription declines.

5. How should licensors model BYDUREON remaining commercial runway?

Model it around payer coverage trajectories and the effective competitive entry window driven by patent status and settlement timing rather than only FDA-level approvals.

---

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA Drug Approval Package for BYDUREON (exenatide extended-release), including labeling and regulatory history. U.S. Food and Drug Administration.

DrugChatter Q&A for BYDUREON

Bydureon formulation patent?
Bydureon patent expiration?
Bydureon market value in 2025?
Bydureon composition of matter patent?
Bydureon loss of exclusivity?